


Fig. 1



RK-163-pulsed human Elu-CD14 positive cell




Fig. 2





Fig. 3

Fig. 4




Fig. 5





Fig. 6

Fig. 7




Fig. 8




Fig. 9





Fig. 10-1



U937
cell

Fig. 10-2





Fig. 10-3

Pre-MACS purification FACS phenotype



peripheral blood
CD14/CD1d
positive cell

post-MACS purification FACS phenotype




Fig. 11




Fig. 12




Fig. 13




Fig. 14A

antitumor effect of RK-163 glycolipid
(comparison with α GalCer)

comparison of number of liver metastasis B16
cells calculated from melanin concentration








Fig. 14B


antitumor #14 melanin measurement




untreated
group front
liver
(N=3) back



unpulsed THP-1
administered
group (3x10⁵)
front




unpulsed U937
administered
group (3x10⁵)
front




administered cells 3x10⁴


RK163-pulsed
THP-1 cell
group
front



1x10⁴



1x10³



RK163-pulsed
U937 cell
group
front








Fig. 15A**Fig. 15B**

Fig. 16A

distribution in major organs




Fig. 16B




Fig. 17A




Fig. 17B





Fig. 18

U937



THP-1 cell proliferation (24 hr pulse-X-irradiation)




Fig. 19A




Fig. 19B

